If you’ve searched GLP-1 for PCOS, Ozempic or Mounjaro, you’ve probably found two camps: “lose 10 kilos fast” and “never talk about weight, it’s all diet culture.” I’ve sat with this question deeply, because two things are true at once. Women with PMOS (formerly PCOS) carry, on average, more mental-health struggles and harder relationships with food. And for someone where weight loss is genuinely indicated, a modest loss can improve ovulation, lower testosterone, and improve metabolic health. So where do GLP-1s actually fit? With what I call ethical PCOS weight loss.
One quick note. This is education, not medical advice, and I’m not your naturopathic doctor. Read it, take notes, then bring it to your own care team.
▶ Liked this video? Subscribe on YouTube.
Thinking about it? Walk through the consent check first.
Shift Society is our community for women navigating PMOS (formerly PCOS) and metabolic health. Members also get my 4-Question Consent Check Worksheet, so you can decide if, when, and how to focus on weight safely. Real science, real talk.
In this article
The honest middle road
Let me be transparent: I have PCOS myself, and since 2010 I’ve worked with thousands of women, which is exactly why I don’t sell one roadmap. The medication question only makes sense inside a bigger frame. Most PMOS care belongs in a weight-neutral lane, and weight loss enters the conversation only when proper screening says it’s indicated, and only with your consent and your full view of the options. A GLP-1 is one of those options, not the starting line. So before we talk about the drug, let’s talk about whether the door should even be open.
Does losing weight actually help PCOS?
The research is genuinely two-sided. A modest 5 to 10% reduction in body weight can improve insulin resistance, ovulation, and cycle regularity in PCOS. That part is real. But the same literature shows the method matters as much as the result: chronic dieting, the up-and-down of weight cycling, and the stress of weight stigma can drive cortisol up, inflammation up, and disordered-eating risk up. So a metabolic gain that costs you your relationship with food isn’t a gain. That tension is the whole reason a medication this effective still needs guardrails around it.
The 4-question consent check
So before any weight-loss plan, a GLP-1 included, I walk through four questions:
- Is it medically indicated right now? We’re reading labs, metabolic markers, and quality of life, not the number on the scale or a deadline you set for an event.
- Are you resourced for it? If there’s a hard history with food, that gets support first. Starting a medication on top of an unaddressed food relationship is building on sand.
- Is your team consent-based? Someone fluent in the metabolic side and the mental-health side, not one without the other.
- Can we measure success past the scale? Energy, cravings, cycles, labs. If the only metric is pounds, the plan is already off.
Where GLP-1s like Ozempic fit
Now the medication itself. GLP-1s like Ozempic and Mounjaro are everywhere in the PCOS conversation, and for a real reason: there’s research in people with PCOS showing they can help insulin resistance, liver fat, and body size. Here’s the nuance I want you carrying into the room. They work largely by quieting appetite, and a durable relationship with food depends on staying connected to your hunger and fullness cues, the very signals the drug turns down. So a GLP-1 can do genuine metabolic work while, if no one’s watching for it, eroding the foundation you’ll lean on when you come off. And coming off matters: regain after stopping is well documented, and the weight cycling that can follow carries its own harm. None of that makes these medications bad. It makes them a tool that works best with scaffolding around it, the mental-health piece, a settled nervous system, hunger-cue support, and the right timing for your life. Whether one is right for you is a decision for you and your prescriber, not a blog post. My job here is to make sure you walk into that decision already holding the questions.
Chase healing, not the scale
This is also why you won’t catch me promising a number of pounds by a certain date, or posting a before-and-after. You’re more than that, and those snapshots never tell the real story. I’m a fan of intuitive eating for rebuilding self-trust and easing food guilt, and I add one PCOS-specific layer: your metabolic health still counts. Intuitive eating says chase healing, not the scale, and I agree completely. In ethical weight loss we chase healing too, and if your body changes as a side effect of that repair, good. Tools, a medication or anything else, are welcome on the same terms: real informed consent, your autonomy honoured, it’s genuinely what you want, the foundation’s been looked at, and the timing is right.
What it looks like in practice
In practice it looks almost ordinary, which is the point. We anchor on metabolic health and how your days actually feel. We build nutrition that nourishes and fits you, lean on protein and fiber to steady hunger cues, and treat movement and sleep as self-respect rather than punishment. We bring stress down so choices get made from a grounded place. And if a tool like a GLP-1 or a supplement is part of the plan, it sits on that foundation instead of replacing it. That’s how you lose weight without losing yourself.
Watch the full video: PCOS Weight Loss (Ethical Weight Loss), and subscribe to my YouTube channel.
Want to go deeper?
For the full step-by-step education, there’s the PCOS Pivot Course, and the PMOS Energy Code is a short challenge for the energy and fatigue piece.
In BC? A free Clarity Call is a short, no-pressure fit chat, not a medical visit.
This article is educational, not medical advice or a diagnosis. Medication decisions, including GLP-1s, belong with your prescriber. If something here resonates, bring it to your healthcare team, who can look at it through the lens of your individual health.
Main references
- Teede HJ, et al. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2023. PubMed

Leave a Reply